Support of this proposition is provided by the promising initial findings made from a recent prospective Phase I study showing the safety and efficacy of the mannitol-induced BBB disruption procedure prior to infusion of Cetuximab in EGFR-positive glioma patients [41]. The gene discussed is EGFR; the disease is central nervous system cancer.